Business · 17/11/2011Updated: 10/17/2026 · 1 min read
National Institutes of Health to Grant Exclusive Patent License for Cannabinoid-Based Therapies for Hepatic Encephalopathy
Summary
The National Institutes of Health is issuing a notice of its intention to grant an exclusive patent license to KannaLife Sciences Inc. for the development of cannabinoid-based therapeutics to treat hepatic encephalopathy in humans, as outlined in U.S. Patent 6,630,507 and PCT Application Serial No. PCT/US99/08769.